Nanox.AI, the medical imaging analytics subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), has taken two strategic steps that could accelerate the adoption of its AI-powered diagnostic tools. The company announced an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, which includes minimum annual license commitments. Separately, an optimization project with Intel demonstrates a path for Nanox.AI’s imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud.
The UK deal matters because approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed. HealthOST is designed to analyze routine CT scans for signs of osteoporosis and vertebral fractures, potentially catching conditions that would otherwise go unnoticed. By partnering with Vertec Scientific, Nanox.AI gains a established distributor with deep relationships in the UK healthcare market, which could speed up adoption among hospitals and imaging centers. The minimum annual license commitments provide a predictable revenue stream and signal confidence in the product’s commercial viability.
The Intel collaboration addresses a critical barrier to AI adoption in healthcare: data privacy and latency. Running AI inference locally on hospital hardware means patient data doesn’t have to leave the premises, which can ease regulatory and security concerns. It also reduces dependence on internet connectivity and cloud computing costs. For Nanox.AI, this could make its imaging AI framework more attractive to hospitals that are hesitant to adopt cloud-based solutions. Together, these moves advance the company’s strategy to monetize the vast amount of unused diagnostic information captured in routine CT scans.
As Read More>> explains, Nanox.AI is targeting the gap between the original indication for a CT scan and the additional anatomical information it may contain, such as details about the spine, coronary arteries, and liver. The company’s AI solutions aim to help clinicians evaluate these incidental findings, potentially leading to earlier interventions and better patient outcomes. For investors, the latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX.
The announcements also highlight the role of InvestorWire in disseminating corporate news. As a specialized communications platform, InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers. These channels help companies like Nano-X Imaging reach a wide audience of investors and journalists. For more information on InvestorWire’s services, including press release enhancement and corporate communications solutions, visit their website. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
